DYNE THERAPEUTICS INC's ticker is DYN and the CUSIP is 26818M108. A total of 77 filers reported holding DYNE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,174 | +107.4% | 33,273 | +66.8% | 0.00% | +100.0% |
| Q1 2024 | $566 | +129.1% | 19,943 | +7.3% | 0.00% | – |
| Q4 2023 | $247 | +69.2% | 18,592 | +13.7% | 0.00% | – |
| Q3 2023 | $146 | -19.3% | 16,348 | +1.3% | 0.00% | – |
| Q2 2023 | $181 | -20.3% | 16,132 | -18.0% | 0.00% | – |
| Q1 2023 | $227 | -0.4% | 19,678 | 0.0% | 0.00% | – |
| Q4 2022 | $228 | -99.9% | 19,678 | +0.0% | 0.00% | – |
| Q3 2022 | $250,000 | +85.2% | 19,677 | +0.4% | 0.00% | – |
| Q2 2022 | $135,000 | -28.9% | 19,599 | -0.4% | 0.00% | – |
| Q1 2022 | $190,000 | -18.8% | 19,669 | +0.1% | 0.00% | – |
| Q4 2021 | $234,000 | -26.9% | 19,644 | -0.4% | 0.00% | – |
| Q3 2021 | $320,000 | -41.1% | 19,718 | -23.7% | 0.00% | -100.0% |
| Q2 2021 | $543,000 | +235.2% | 25,830 | +148.4% | 0.00% | – |
| Q1 2021 | $162,000 | -25.7% | 10,400 | 0.0% | 0.00% | – |
| Q4 2020 | $218,000 | – | 10,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vida Ventures Advisors, LLC | 2,960,046 | $35,195,000 | 13.16% |
| MPM ASSET MANAGEMENT LLC | 4,951,303 | $58,871,000 | 12.72% |
| Atlas Venture Life Science Advisors, LLC | 8,934,902 | $106,236,000 | 9.76% |
| Logos Global Management LP | 3,234,392 | $38,457,000 | 3.97% |
| GREAT POINT PARTNERS LLC | 845,000 | $10,047,000 | 2.23% |
| Deep Track Capital, LP | 2,292,250 | $27,255,000 | 1.92% |
| Octagon Capital Advisors LP | 583,649 | $6,940,000 | 1.35% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 476,000 | $5,641,000 | 1.26% |
| COMMODORE CAPITAL LP | 305,125 | $3,628,000 | 0.84% |
| RA Capital Management | 2,805,045 | $33,352,000 | 0.59% |